Finance


High Tide Secures Commitment Letter from Connect First Credit Union for Non-Dilutive Financing

August 18th, 2022 - Ryan Allway

CALGARY, August 18, 2022 /CNW/ – High Tide Inc. (“High Tide” or the “Company”) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets, announced today that it has entered into a binding commitment letter with Connect First Credit Union Ltd. (“connectFirst”) for a $19 million […]

How to Capitalize on Germany’s Move to Legalize Cannabis

November 30th, 2021 - Ryan Allway

Germany’s incoming governing parties recently announced a formal agreement to legalize adult-use cannabis when they take power. While personal possession has already been decriminalized, the new proposal seeks to establish a regulated market for adult-use cannabis. The move could create an industry like those in Canada and some U.S. states. While the legislation won’t be […]

While Psychedelics Wait, Ketamine Revenues Roll On

November 30th, 2021 - Ryan Allway

The nature of the psychedelic market today means that public company investors are making largely speculative investments. Though there are plenty of studies demonstrating the efficacy of substances ranging from LSD to psilocybin to MDMA, the fact remains they are Schedule 1 controlled substances and have not been approved for therapeutic use. Companies seeking such […]

Silo Pharma Looks to Become a NASDAQ Biotech

October 4th, 2021 - Ryan Allway

Silo Pharma Inc. (OTCQB: SILO) is a cutting-edge, development-stage biotechnology company focused on merging traditional therapeutics with emerging psychedelic research for people suffering from indicators such as depression, post-traumatic stress disorder, Parkinson’s disease, and other rare neurological disorders, representing billion-dollar markets. The company submitted an initial application to list on the NASDAQ Capital Market—a move […]

KetamineOne Applies Cutting-Edge Tech & Research to Enhance Psychedelic Therapies Across Growing Clinic Network

August 11th, 2021 - Ryan Allway

The psychedelic renaissance has taken the research community by storm, but psilocybin, DMT, MDMA, and other therapies remain in development. Ketamine is the only widely available psychedelic therapy that the FDA approves to treat depression and suicidal ideations. As a result, investors may want to start there for near-term opportunities. Let’s take a look at […]

New CBD Trials Point the Way for Enveric, MagicMed

July 30th, 2021 - Ryan Allway

  As the cannabis industry strives to gain widespread acceptance in the mainstream, scientific studies into the potential benefits of the plant and its active ingredients play a key role in reaching that goal. There are currently very few approved pharmaceutical drug applications for cannabinoids, but that could change. After decades of effective prohibition there […]

Premium Brand Leader Upping the Ante for Cannabis 2.0 Products

July 21st, 2021 - Ryan Allway

Canada made whole new classes of cannabis products legal for recreational use in October 2019. Hailed as Cannabis 2.0, the introduction of products such as vapes, oils, and edibles was anticipated to offer a new high-growth category in the already booming legal cannabis industry. Due to a variety of factors, including an uneven regulatory rollout […]

Ketamine One Aims to Become a North American Mental Health Leader

July 12th, 2021 - Ryan Allway

Nearly one in five Americans were living with a mental illness or addiction in 2019, according to the National Institutes of Health. While the U.S. spends $16 billion on mental health treatments and ancillary services each year, challenges connecting with patients, significant adverse side effects, and other factors have made the problem difficult to overcome. […]

Enveric Bio’s Acquisition of MagicMed Accentuates Strengths of Each Company

July 8th, 2021 - Robin Lefferts

  When two companies merge, or one is acquired by another, the reasoning behind the deal often falls into one of two categories. Either the companies are competitors with the merged entity grabbing a larger portion of their shared market, or they are complementary and perhaps working in adjacent fields. In either case, the strengths […]

MedXtractor Fills a Key Gap in Mental Health Treatments

June 30th, 2021 - Ryan Allway

  According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. MedXtractor Corp.’s (CSE: MXT) (OTC: […]

Decibel Appoints Paul Wilson as CEO

June 22nd, 2021 - Ryan Allway

CALGARY, AB, June 22, 2021 /PRNewswire/ – Decibel Cannabis Company Inc. (the “Company” or “Decibel”) (TSXV: DB) (OTCQB: DBCCF), a premium cannabis producer, is pleased to announce  the appointment of Paul Wilson as its Chief Executive Officer, effective Wednesday, June 23rd. Emphasizing the Company’s objective for brand growth, Mr. Wilson brings CEO and President level experience from some of Canada’s top consumer brands […]

RYAH Medtech Expanding Internationally with Flurry of Deals

June 3rd, 2021 - Robin Lefferts

  A sometimes overlooked aspect of the cannabis industry is the global potential for North American companies. To be sure, the United States and Canada represent the largest and most mature legal cannabis markets, and many companies are rightfully focused on them exclusively. But some companies are set up to not only capitalize on these […]

Hemptown Announces $7.5M Concurrent Financing to Proposed Qualifying Transaction

May 27th, 2021 - Ryan Allway

Vancouver, British Columbia–(Newsfile Corp. – May 27, 2021) – Hemptown Organics Corp. (the “Company” or “Hemptown“), a privately held British Columbia company is providing an update further to its news releases of September 9, 2020, October 2, 2020, October 13, 2020 and March 23, 2021 on the proposed acquisition of Hemptown by Spectre Capital Corp. […]

Pre-Public Hempsana Moving Quickly in Cannabis Derivatives Market

May 7th, 2021 - Robin Lefferts

  Widely hailed as Cannabis 2.0, the current phase of growth in the legal cannabis market is fueled by cannabis-derived products based on oils, distillates, and isolates. These extracts contain various active ingredients, or cannabinoids, like CBD, THC, and rare cannabinoids such as CBN, CBG and Delta-8 THC. You may have noticed the explosion of […]

Revive Takes a Step Closer to Launching New Psychedelic Delivery Mechanism

April 30th, 2021 - Ryan Allway

  Mental illness is the leading cause of disability in developed countries. In fact, half of Americans will experience mental illness in their lifetime and $350 billion is spent each year on treating depression in the U.S. and Europe alone. Psychedelics have emerged as a breakthrough treatment for many mental health disorders with fast-acting results, […]

There’s no Magic Answer to the Question, “Can I Patent Magic Mushrooms?”

February 24th, 2021 - Ryan Allway

“Patent pending” is a phrase you are likely familiar with. You have seen it stamped on the side of some doodad at the mall or heard it on the TV show that you are binge watching, and you think to yourself, “Wow, I wish I could invent something that everyone thinks is really cool”. Most […]

How California is Dominating the Cannabis Brand Landscape

February 24th, 2021 - Ryan Allway

California is well known for its brand dominance—from its Hollywood studios to its Napa Valley wines. As a tastemaker across industries, the state’s cannabis brands are well-positioned to follow in these footsteps and expand across the United States if and when the federal government legalizes cannabis nationwide. At the same time, manufactured products including gummies, […]

Cannabis 3.0: Investing in Profitability

February 23rd, 2021 - Ryan Allway

If you’ve been following the public cannabis markets for the past decade, you’ve seen a myriad of changes that can be bundled into a few major categories: The Canadian build up, the rise of the US MSO and the race to get profitable.  During the Canadian build up, call it Cannabis 1.0, it was all […]

Big Pharma Dives Into CBD: Who Could Be Next?

February 22nd, 2021 - Robin Lefferts

As many of you know, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) agreed in early February to acquire GW Pharmaceuticals plc (NASDAQ: GWPH) for a total price tag, including cash and shares, of $7.2 billion. GW Pharma is a pioneer in cannabinoid-based medicine, and its cannabidiol (CBD) formulation Epidiolex® is notably the first plant-derived cannabinoid medicine ever […]

Psychedelic Clinical Trials & Who’s Behind Them

February 18th, 2021 - Ryan Allway

The psychedelics industry has experienced unprecedented growth over the past few years, driven by a combination of emerging research, regulatory support and investor interest. With a growing number of organizations in the space, it can be difficult for investors to keep track of what clinical trials are ongoing and what opportunities lie in the horizon. […]

Revive Therapeutics Aims to Bring Psychedelics to Market

February 17th, 2021 - Ryan Allway

The psychedelic drug market is projected to grow at a 16.3% compound annual growth rate to reach nearly $7 billion by 2027, according to Data Bridge Market Research. While there are a growing number of publicly traded companies in the space, the best opportunities have the right combination of experience, intellectual property and clinical trials. […]

Kaya Reaches Beyond Oregon

February 17th, 2021 - Ryan Allway

  In early 2014, in a small office in Hollywood, Florida, the management of what is today Kaya Holdings made the strategic decision to transition their existing small-cap publicly traded biofuels company away from alternative energy and exclusively toward the cultivation and retail of legal cannabis. This was no ordinary decision; Colorado and Washington had […]

ManifestSeven Doubles Down on Emerald Triangle with New Facility

February 9th, 2021 - Ryan Allway

California’s legal cannabis industry is on track to reach $7.2 billion in sales by 2024, according to Arcview Market Research and BDS Analytics, which represents a 19% compound annual growth rate. The Emerald Triangle region is widely considered to be the epicenter of that growth with its ideal microclimate and world-class operators. Let’s take a […]

Next Green Wave: A Hidden Gem in the Cannabis Industry

January 28th, 2021 - Ryan Allway

  The cannabis industry is projected to hit $30 billion in sales by 2023, according to Marijuana Business Daily, with California representing about 34% of U.S. sales. While there are many publicly traded companies in the space, there are only a handful that are growing and profitable with a truly experienced team both in the […]

Delic Looks to Build a Sprawling ‘Psychedelic Ecosystem’

January 20th, 2021 - Ryan Allway

There have been a number of high profile initial public offerings in the psychedelic space, including COMPASS Pathways’ (NASDAQ: CMPS) $2 billion debut. While there are now more than 30 publicly traded companies in the space, there are thousands more private companies at various stages of funding and development.  Delic Corp. (CSE: DELC) (OTCQB: DELCF) […]

How to Invest in Cannabis Delivery

January 18th, 2021 - Ryan Allway

Delivery services of all kinds experienced record-breaking growth in 2020 thanks to a global pandemic that has depressed retailers, restaurants, and grocery stores. Of course, these trends are just an acceleration of an existing transition from brick-and-mortar to e-commerce—a trend that many in the cannabis industry are betting will be transformative. Let’s take a look […]

CBD Innovator, HempFusion, Makes Successful Debut on TSX

January 13th, 2021 - Ryan Allway

  HempFusion Wellness Inc. (TSX: CBD-U) shares soared over 65% following their successful debut on the Toronto Stock Exchange (TSX) on Wednesday, January 6, 2021. Cannabidiol, or CBD, has become one of the most popular health and wellness products in the world over the past couple of years. According to Research and Markets, the global […]

HempFusion Gears Up for IPO on the TSX

December 7th, 2020 - Ryan Allway

HempFusion Wellness Inc., a leading health and wellness CBD company, recently closed the order book for its proposed initial public offering (IPO), marking another step closer to becoming a publicly-traded company on the Toronto Stock Exchange (TSX) over the coming months. Completion of this proposed initial public offering has the potential to accelerate the company’s […]

ManifestSeven: The Importance of Cannabis Distribution

November 23rd, 2020 - Ryan Allway

  Most cannabis investors are familiar with cultivation operations and dispensaries, but distribution is quickly becoming one of the industry’s most important components. Although distribution plays a big role in other regulated industries, the cannabis industry has only begun recently to recognize the critical role of distributors in the ecosystem. Let’s take a look at […]

CBD Makes Its Way into Mainstream Retail

November 19th, 2020 - Ryan Allway

The U.S. market for CBD products is projected to reach $23.7 billion by 2023, according to Brightfield Group, representing a seven-fold increase in the market’s size. While it’s one of the fastest-growing subsets of the multi-trillion-dollar wellness industry, CBD products remain absent from most mass-market retailers. CVS became the first large-scale retailer to offer CBD […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading